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To the Editor:
Lara et al. have recently reported 
in this Journal a pooled analysis of 
three Southwest Oncology Group trials 
performed in 329 pretreated extensive-
stage small cell lung cancer (SCLC) 
patients aiming to assess whether plat-
inum-sensitivity status is associated 
with survival outcomes.1 Sensitivity 
to first-line chemotherapy has always 
been considered as the main driver of 
second-line therapy outcome in SCLC. 
For this reason, relapsed SCLC has 
been traditionally classified into sensi-
tive and resistant disease according to 
the type of response to first-line ther-
apy and to treatment-free interval (TFI, 
longer or shorter than 60–90 days). 
However, as also underlined by Lara et 
al., this definition was designed many 
years ago and based on a small patient 
series,2 and its validity has been put 
under discussion by some more recent 
studies.1,3
On the basis of this consider-
ations, we have recently performed a 
meta-analysis of six trials of intrave-
nous topotecan-based second-line ther-
apy aimed at validating the currently 
used criteria for defining sensitive/
resistant relapsed SCLC and to assess 
the prognostic impact of sensitive/resis-
tant categories and of other clinical fac-
tors.4 Our study has confirmed the value 
of standard criteria for relapsed SCLC 
outcome prediction. In particular, 
patients with TFI less than 60 days had 
a worse survival outcome; in addition, 
is, cytotoxic agent was included in 
only one of the three trials.
The concept of platinum sensi-
tivity was established based on retro-
spective analysis of the clinical trials 
of second-line chemotherapy with 
cytotoxic agents,2,3,4 and the useful-
ness of the concept has been con-
firmed as long as we used cytotoxic 
agents for second-line treatment.5,6 
The authors’ conclusion may be cor-
rect when noncytotoxic agents, such 
as molecularly targeted agents, are 
used for second-line chemotherapy; 
however, we believe that the tradi-
tional concept still works and should 
be referred to as ever when cytotoxic 
agents are used as second-line treat-
ment in both clinical trial and clinical 
practice settings.
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To the Editor:
Lara et al. have recently reported 
a retrospective study on data from the 
Southwest Oncology Group aiming 
to evaluate the association between 
platinum-sensitivity status and clini-
cal outcome in patients with relapsed 
or refractory small-cell lung cancer. In 
the study, patient-level data from three 
recent Southwest Oncology Group tri-
als for second-line and/or third-line 
extensive-stage small-cell lung cancer 
were pooled and analyzed, and they 
concluded that platinum-sensitivity 
status might no longer be as strongly 
associated with post-progression sur-
vival in the modern era.1
In the article, they mentioned 
a defect of their study in that tri-
als included in their analysis had no 
or little activity, and they stated that 
they, therefore, could not rule out the 
possibility that platinum-sensitivity 
status might influence the outcome 
in patients receiving active therapies; 
however, they did not refer to the bias 
of the included trials in their analysis, 
and we consider that this is a critical 
defect of the study. Trials included 
in their analysis were for bortezo-
mib (proteasome inhibitor), sorafenib 
(vascular endothelial growth factor 
receptor tyrosine kinase inhibitor), 
and topotecan ± aflibercept (vascular 
endothelial growth factor-trap); that 
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